Medical Device Technologies Market Size, Share, Trends With Top Key Players briefingwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from briefingwire.com Daily Mail and Mail on Sunday newspapers.
F. Hoffmann-La Roche Ltd
Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs
Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs
cobas® pure integrated solutions brings together three diagnostic technologies
1 on a single platform to optimise space and resources in small to medium laboratory settings
With a footprint of just two square meters, this new analyser provides small to medium sized labs with access to more than 230 diagnostic tests
2 across a wide-range of disease areas including infectious diseases, oncology and cardiology
Through automation of manual tasks, Roche’s new solution is designed to simplify workflows and improve the productivity of lab personnel whilst also supporting the delivery of better patient care
Roche Annual General Meeting 2021
All proposals of the Board of Directors approved
Christoph Franz re-elected as Chairman of the Board of Directors; all current Board members re-elected
34th consecutive dividend increase to CHF 9.10 per share
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). Owing to the pandemic restrictions, the AGM was held with only those persons required by the Articles of Incorporation in attendance and with no shareholders physically present. Roche shareholders were able to exercise their rights via written or electronically submitted instructions to the independent proxy, Testaris AG. The independent proxy represented 84.58% of the total of 160,000,000 shares. The Management Report, the Annual Financial Statements and the Consolidated Financial Statements for 2020 were approved.
Medical Device Technologies Market to Witness Astonishing Growth during Forecast 2025 The Global Medical Device Technologies Market 2021-2025 Report provides an in-depth analysis on the studied market that helps to seem at the longer term requirement also as prediction.
BriefingWire.com, 3/12/2021 - The Global Medical Device Technologies Market 2021-2025 Report provides an in-depth analysis on the studied market that helps to seem at the longer term requirement also as prediction. The medical device technologies market Report evaluates the market by key market players, opportunities, value, trends, growth, market share, market competition landscape, recent developments and sales volume analysis. Additionally, it magnifies the chance for decision-making and helps create an efficient counter-strategy to realize a competitive advantage. The report provides up-to-date review of the present global market scenario, the newest development
F. Hoffmann-La Roche Ltd
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
The REMDACTA clinical trial of Actemra/RoActemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone
Roche will submit the REMDACTA results to a peer-reviewed journal
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiv